Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The target discovery process.

Ursula Egner1, Jörn Krätzschmar, Bertolt Kreft

  • 1Research Center Europe, Enabling Technologies, Schering AG, 13342 Berlin, Germany. ursula.egner@schering.de

Chembiochem : a European Journal of Chemical Biology
|March 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer.

Nature·2026
Same author

Long-Term Outcomes After Multiorgan Resection of Primary Gastrointestinal Stromal Tumors.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026
Same author

mRAVE governs lysosomal catabolism through basal and mTORC1-regulated V-ATPase assembly.

The EMBO journal·2026
Same author

Integration and validation of complementary ex vivo assays for functional precision oncology.

NPJ precision oncology·2026
Same author

Scalable hypothalamic neuron differentiation from human pluripotent stem cells suitable for modeling metabolic disorders.

Stem cell reports·2026
Same author

Robotic versus laparoscopic Roux-en-Y gastric bypass: a propensity-matched comparison of the inflammatory response and MASLD trajectories.

Journal of robotic surgery·2026
Same journal

Reaction Optimization for Enzymatic Deconstruction of Industrially Relevant Nylon Composites.

Chembiochem : a European journal of chemical biology·2026
Same journal

Deploying Artificial Metalloenzymes in Complex Environments: Strategies and Applications.

Chembiochem : a European journal of chemical biology·2026
Same journal

Synthetic Ligands of Myeloid C-Type Lectin Receptors.

Chembiochem : a European journal of chemical biology·2026
Same journal

Vancomycin-Mediated Binding of DNA Origami Nanostructures to Gram-Positive and Gram-Negative Bacteria.

Chembiochem : a European journal of chemical biology·2026
Same journal

Mutasynthesis and Antibiotic Activity of Mupirocin Analogues.

Chembiochem : a European journal of chemical biology·2026
Same journal

Pressure-Dependent Aromatic Ring Flips Reveal Variable Transition-State Volume and Compressibility Among Structural Regions of BPTI.

Chembiochem : a European journal of chemical biology·2026
See all related articles

A structured target discovery process minimizes drug development attrition by selecting ideal kinase targets. This ensures drug candidates have therapeutic effects with fewer side effects.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Drug Development

Background:

  • High attrition rates in drug development necessitate improved early-stage processes.
  • Kinase targets are crucial in many therapeutic areas, but their selection requires rigorous evaluation.

Purpose of the Study:

  • To outline a systematic target discovery process for kinase inhibitors.
  • To enhance the success rate of drug development projects by ensuring robust target selection.

Main Methods:

  • The process involves three key stages: target selection, target assessment, and target validation.
  • Criteria include general, indication-specific, descriptive, and functional parameters.

Main Results:

  • This rational approach ensures therapeutic targets meet predefined criteria.

Related Experiment Videos

  • It maximizes the probability of developing selective small-molecule inhibitors.

    • Conclusions:

    • A well-defined target discovery process is essential for minimizing attrition in drug development.
    • This strategy increases the likelihood of achieving efficacy with reduced in vivo side effects, grounded in strong biological rationale.